Clinical Pharmacology Indian Medical PG Practice Questions and MCQs
Practice Indian Medical PG questions for Clinical Pharmacology. These multiple choice questions (MCQs) cover important concepts and help you prepare for your exams.
Clinical Pharmacology Indian Medical PG Question 1: Which of the following statements is true regarding competitive reversible antagonism?
- A. ED50 remains unchanged in competitive reversible antagonism.
- B. Efficacy and Vmax remain unchanged. (Correct Answer)
- C. Potency remains unchanged in the presence of a competitive antagonist.
- D. Affinity (Kd) remains unchanged in competitive reversible antagonism.
Clinical Pharmacology Explanation: ***Efficacy and Vmax remain unchanged.***
- In competitive reversible antagonism, the antagonist binds to the same receptor site as the agonist but can be overcome by increasing the agonist concentration [2]. This means the **maximum effect (efficacy or Vmax)** of the agonist can still be achieved, although a higher dose is needed [2].
- The antagonist does not alter the intrinsic ability of the agonist to produce a full response, only its **apparent affinity** for the receptor.
- This is the hallmark of competitive reversible antagonism: **rightward shift of the dose-response curve with no change in maximum response** [2].
*Potency remains unchanged in the presence of a competitive antagonist.*
- **Potency** is a measure of the amount of drug needed to produce a given effect (often defined by EC50 or ED50) [3].
- A competitive antagonist requires a **higher concentration of agonist** to achieve the same effect, thus **decreasing the apparent potency** of the agonist [4].
- The dose-response curve shifts to the right (parallel shift) [4].
*ED50 remains unchanged in competitive reversible antagonism.*
- **ED50 (effective dose 50)** is the dose that produces 50% of the maximum effect.
- Because competitive antagonists shift the dose-response curve to the right, a **higher ED50** is required to achieve 50% of the maximum effect in the presence of an antagonist [4].
*Affinity (Kd) remains unchanged in competitive reversible antagonism.*
- The **dissociation constant (Kd)** represents the affinity of a drug for its receptor [1].
- In competitive reversible antagonism, the antagonist increases the **apparent Kd** of the agonist (reduces apparent affinity), requiring more agonist to achieve receptor occupancy.
- The **intrinsic Kd** of the agonist doesn't change, but its apparent affinity is reduced due to competition with the antagonist.
Clinical Pharmacology Indian Medical PG Question 2: Which is the first step in carrying out an Adverse Event Following Immunization (AEFI)?
- A. Confirm information in report (Correct Answer)
- B. Collect data about the suspected vaccine
- C. Observe the immunization service in action
- D. Formulate a working hypothesis
Clinical Pharmacology Explanation: ***Confirm information in report***
- The initial and crucial step is to **verify the accuracy and completeness of the reported information** to ensure reliable data for further investigation.
- This involves checking details such as the **patient's demographics, vaccine administered, date of vaccination, and the reported adverse event** itself.
*Collect data about the suspected vaccine*
- While essential for an AEFI investigation, **collecting specific vaccine data comes after confirming the initial report**, as you first need a verified event to investigate.
- This step focuses on the **vaccine's batch number, expiry date, and manufacturer**, which are vital for causality assessment but not the very first action.
*Observe the immunization service in action*
- **Observing the immunization service** is a step that might be taken later in an investigation if a program error or procedural issue is suspected, not the immediate first step for an individual AEFI.
- This helps identify **potential programmatic errors** in vaccine administration or storage, which is a downstream investigative measure.
*Formulate a working hypothesis*
- **Formulating a working hypothesis** is part of the analytical phase of an AEFI investigation, which occurs after initial data collection and confirmation, not as the very first step.
- A hypothesis guides further investigation into potential causes but requires **initial confirmed data** to be meaningful.
Clinical Pharmacology Indian Medical PG Question 3: Volume of distribution of a drug is 500 ml and target concentration of drug in blood is 5 g/L. 20% of administered drug is reached to systemic circulation. What will be the loading dose of that drug -
- A. 1 gm
- B. 5 gm
- C. 25 gm
- D. 12.5 gm (Correct Answer)
Clinical Pharmacology Explanation: ***12.5 gm***
- The formula for loading dose (LD) is: LD = (Target Concentration × Volume of Distribution) / Bioavailability.
- Given: Target Concentration = 5 g/L, Volume of Distribution = 500 mL = 0.5 L, Bioavailability = 20% = 0.2.
- So, LD = (5 g/L × 0.5 L) / 0.2 = 2.5 g / 0.2 = **12.5 g**.
*1 gm*
- This value would be obtained if the target concentration was 2 g/L with 100% bioavailability, or if the calculation incorrectly handled the volume or bioavailability factor.
- It does not account for the specified **bioavailability of 20%** or the given target concentration and volume of distribution.
*5 gm*
- This result would be obtained if the bioavailability was assumed to be 50% (LD = 2.5 g / 0.5 = 5 g), or if the volume of distribution was incorrectly used in the calculation.
- This option does not correctly factor in the **20% bioavailability** of the administered drug.
*25 gm*
- This value would result from mistakes such as dividing by bioavailability of 10% instead of 20% (LD = 2.5 g / 0.1 = 25 g), or by multiplying bioavailability instead of dividing by it.
- This answer significantly **overestimates** the required dose, which could lead to drug toxicity.
Clinical Pharmacology Indian Medical PG Question 4: Which of the following statements is correct regarding the given graph?
- A. Drug 1 represents agonist and drug 2 represents inverse agonist
- B. Drug 3 represents agonist and drug 4 represents inverse agonist
- C. Drug 2 represents partial agonist and drug 3 represents inverse agonist
- D. Drug 1 represents agonist and drug 4 represents inverse agonist (Correct Answer)
Clinical Pharmacology Explanation: ***Drug 1 represents agonist and drug 4 represent inverse agonist***
- **Drug 1** demonstrates maximal efficacy, producing a **supraphysiologic response** above the baseline (100%), characteristic of an **agonist**.
- **Drug 4** produces a response **below the baseline** (100%), indicating inhibition of constitutive receptor activity, which is the definition of an **inverse agonist**.
*Drug 1 represents agonist and drug 2 represents inverse agonist*
- While **Drug 1** is correctly identified as an **agonist** due to its maximal effect above baseline, **Drug 2** is a **partial agonist**, as it produces a submaximal effect above baseline but does not reach the full agonist's efficacy.
- **Drug 2** does not reduce the baseline response, so it cannot be an inverse agonist.
*Drug 3 represents agonist and drug 4 represents inverse agonist*
- **Drug 3** maintains the **baseline response** (at 100%) regardless of concentration, indicating it is a **neutral antagonist** or has no effect, not an agonist.
- **Drug 4** is correctly identified as an **inverse agonist** because it reduces the baseline receptor activity.
*Drug 2 represents partial agonist and drug 3 represents inverse agonist*
- **Drug 2** is correctly identified as a **partial agonist** as it produces an effect above baseline but less than a full agonist.
- **Drug 3** is incorrect; it shows no change from baseline (100%), reflecting a **neutral antagonist** or inactive substance, not an inverse agonist which would decrease the baseline response.
Clinical Pharmacology Indian Medical PG Question 5: Which of the following is the most fundamental criterion that must be met by a disease before it is to be considered suitable for a screening programme?
1. The natural history of the disease should be adequately understood.
2. No effective treatment should exist for the disease.
3. The disease should not have a recognizable latent or asymptomatic stage.
4. There should be a test that can detect the disease prior to onset of signs and symptoms.
- A. 4. There should be a test that can detect the disease prior to onset of signs and symptoms.
- B. 3. The disease should not have a recognizable latent or asymptomatic stage.
- C. 1. The natural history of the disease should be adequately understood. (Correct Answer)
- D. 2. No effective treatment should exist for the disease.
Clinical Pharmacology Explanation: ***The natural history of the disease should be adequately understood.***
* This is the **most fundamental criterion** because understanding the natural history (progression from asymptomatic to symptomatic disease) allows for the identification of a **critical window** for early intervention through screening.
* Without this knowledge, it's impossible to determine when to screen, what to screen for, or whether early detection will lead to a better outcome.
*There should be a test that can detect the disease prior to onset of signs and symptoms.*
* While important, the existence of a detectable test *before* symptoms is only useful if the **natural history** is understood, allowing for appropriate timing and interpretation of the test.
* A test without understanding the disease's progression might lead to **overdiagnosis** or diagnosis at a stage where intervention is no longer effective.
*The disease should not have a recognizable latent or asymptomatic stage.*
* This statement is incorrect; a disease *must* have a **recognizable latent or asymptomatic stage** to be suitable for screening.
* Screening aims to detect disease **before** symptoms appear, making the existence of such a stage essential for successful early intervention.
*No effective treatment should exist for the disease.*
* This statement is incorrect; for a screening program to be beneficial, an **effective treatment must exist** for the disease once detected.
* Screening without effective treatment options would merely lead to earlier diagnosis without improving patient outcomes, causing unnecessary anxiety and burden.
More Clinical Pharmacology Indian Medical PG questions available in the OnCourse app. Practice MCQs, flashcards, and get detailed explanations.
